ClinicalTrials.gg

TargetBeta

CD7

CD7 molecule · also GP40, LEU-9, TP41, Tp40 · CD molecules

3 programs in company-led studies act on CD7, from 2 companies: 0 in phase 3. Each with where its target was read from.

Programs

Furthest phase first. A target read by rule is marked rule (3 of them); the others are the company’s own words or a reading by Claude, each quoted on the program’s page.

ProgramCompanyFurthest phaseStudiesAlso acts onRead from
Autologous Anti-CD7 CAR T Cells PA3-17rulePersonGen BioTherapeutics (Suzhou)phase 263 running–NCIt
Anti-CD7 CAR-T Cells RD13-02ruleNanjing Bioheng Biotechearly phase 111 running–NCIt
UTAA07rulePersonGen BioTherapeutics (Suzhou)early phase 111 running–the studies' text

Primary completions ahead

Each program’s next study to reach its primary completion, by the sponsor’s estimate.

  • Dec 31, 2027UTAA07 · PersonGen BioTherapeutics (Suzhou) · early phase 1 · NCT07338604

What this can’t show

  • Only programs whose target has been read: most early programs are named only by a code and their companies do not say what they act on.
  • A target read by rule can be wrong; each program’s page quotes the words it was read from.
  • “Acts on” does not say how: an agonist and an antagonist of the same receptor are listed together (avexitide blocks the GLP-1 receptor that semaglutide activates).
  • Programs in company-led studies on ClinicalTrials.gov with a study in the last two years; academic studies and other registries are not counted here.